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Microalbuminuria as a simple 
predictor of incident diabetes over 
8 years in the Korean Genome and 
Epidemiology Study (KoGES)
Dong-Hyuk Jung1, Young-Sup Byun2, Yu-Jin Kwon1 & Gwang-Sil Kim2
Microalbuminuria (MAU) is a common subclinical disease and related with cardiovascular outcome 
both in diabetic and non-diabetic patients. However, there is rare data about the effect of MAU on 
the development of diabetes. Thus, we aimed to investigate whether MAU is associated with the 
development of incident diabetes. A total of 3385 subjects without diabetes (1503 men and 1882 
women; mean age, 53 years) who participated in the Ansung–Ansan cohort study from 2001–2002 
(baseline) to 2011–2012 (fifth follow-up visit) were followed for a mean of 8 years. The prevalence of 
MAU at baseline was 10.8% (365 patients), and the incidence of newly developed diabetes during the 
follow-up period was 15.3% (56 patients) in subjects with MAU. The hazard ratio (HR) for development 
of diabetes was 1.43 (95% confidence interval (CI) 1.07–1.91, p-value 0.016), independent of traditional 
risk factors for diabetes including pre-diabetes, age, obesity, and family history. The impact of MAU on 
diabetes was also significant in the non-pre-diabetic population (HR 2.08, 95% CI 1.07–4.03, p-value 
0.031). In conclusion, our results show that incident MAU is associated with future development of 
diabetes and could be an early marker for diabetes, even in the non-prediabetic population.
Microalbuminuria (MAU) is a common subclinical disease whose prevalence ranges from 5–7% in the general 
population1 and is about 30% in patients with hypertension (HTN)2. MAU is an established predictor of micro 
and macrovascular complications in patients with type 2 diabetes. However, recent epidemiological and experi-
mental data have indicated that MAU is an early marker of target organ damage and is associated with all-cause 
mortality, CVD incidence, and progression of chronic kidney disease in non-diabetic subjects3–5. In addition, sev-
eral studies have reported that insulin resistance or prediabetes is associated with MAU6–8. However, few studies 
have explored the effect of MAU on the development of diabetes in the non-diabetic population.
We therefore aimed to investigate whether MAU is associated with the development of incident diabetes in the 
general Korean population using data from the Korea Genome and Epidemiology Study (KoGES).
Research Design and Methods
Study Population. Study subjects were individuals who participated in the Ansung–Ansan cohort study 
from 2001–2002 (baseline) to 2011–2012 (fifth follow-up visit). The Ansung–Ansan cohort study is an ongoing 
study that began in 2001 and involves biennial follow-up examinations. A total of 10038 patients were initially 
enrolled in the cohort. The design and baseline characteristics of the Ansung–Ansan cohort study have been pre-
viously published9,10. In this study, we included 4297 subjects whose urine albumin-to-creatinine ratio (UACR) 
was analysed at the first visit. From these 4297 subjects, we excluded 512 who had underlying diabetes and 400 
who did not attend their follow-up examinations. Finally, a total of 3385 subjects without diabetes (1503 men 
and 1882 women; mean age, 53 years) were enrolled in the study. Subjects were followed for a mean of 8 years. 
Informed consent was obtained from all study subjects. The study protocol was approved by the ethics committee 
of the Korean Centre for Disease Control and the Yonsei University School of Medicine Institutional Review 
Board.
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and performed according to the principles of the Declaration of Helsinki. All data generated during this study 
are available.
Clinical and biochemical parameters. Study data included medical history, physical examination, infor-
mation provided by a questionnaire, anthropometric measurements, and laboratory measurement. Information 
on medical history, family history, current use of medications, weekly alcohol consumption, and smoking status 
were obtained from all participants using a standard questionnaire.
Waist circumference was measured three times at the midpoint between the bottom of the ribcage and the top 
of the iliac crest using a fiberglass tape measure. Blood pressure was measured in the sitting position after 5 min 
of rest using a standard mercury sphygmomanometer.
Body mass index (BMI) was calculated as weight divided by height squared (kg/m2). Physical activity was 
classified into the following three categories: none, irregular (≤2 episodes/week), and regular (≥3 episodes/week) 
exercise. One episode of exercise was defined as exercising for at least 30 min. The International Obesity Task 
Force (IOTF) and World Health Organization (WHO) regional office for the Western Pacific region recommend 
defining obesity in Asians as a BMI ≥ 25 kg/m2. Subsequently, the Korean Society for the Study of Obesity (KSSO) 
adopted this definition. Thus, subjects were classified as “generally obese” if their BMI was ≥25 kg/m2. Abdominal 
obesity was defined as a waist circumference ≥90 cm for male subjects and ≥85 cm for female subjects according 
to the criteria of the modified National Cholesterol Education Program’s Adult Treatment Panel III (NCEP ATP 
III) Asian criteria for metabolic syndrome. Collected blood samples were delivered to and analysed at a central 
laboratory (Seoul Clinical Laboratories, Seoul, Korea). Plasma glucose, total cholesterol, triglycerides, and HDL 
cholesterol levels were determined using a Hitachi 747 chemistry analyser (Hitachi, Tokyo, Japan). The LDL cho-
lesterol level was calculated using Friedewald’s equation. The HbA1c level was measured by high-performance 
liquid chromatography on a Variant II instrument (BioRad Laboratories, Hercules, CA).
Definitions of MAU, diabetes, and prediabetes. MAU was defined as an UACR of 30–300 mg/g. We 
excluded overt albuminuria, defined as UACR > 300 mg/g. diabetes was defined as one of the following: (1) 
self-reported history of diabetes; (2) HbA1c level ≥6.5%; or (3) use of an antidiabetic agent or insulin. Prediabetes 
was defined as a fasting plasma glucose level of 110 to 125 mg/dl or an HbA1c concentration of 5.7–6.4%.
Statistical analyses. Data are expressed as mean and SD or as the number and percentage. Comparisons 
of baseline variables with respect to the presence or absence of MAU were analysed using Student’s t test for con-
tinuous variables; categorical variables were analysed using the x2 test. We calculated the hazard ratios (HRs) for 
incident diabetes using Cox proportional hazards models with potential confounding variables. We included tra-
ditional risk factors for diabetes such as age, obesity, family history of diabetes, smoking status, physical activity 
and prediabetes in univariate analyses. Variables with p < 0.15 in the univariate analysis were entered into mul-
tivariate analysis. We developed two different models to estimate the risk of new onset diabetes. The basic model 
was based only on the parameters that were easy to assess without biochemical testing. The risk factors for the 
incidence of diabetes in the basic model were: age, family history of diabetes and obesity. Clinical model was cre-
ated by adding MAU to the basic model. For each model, the area under a receiver operating characteristic curve 
(AROC) was calculated. Comparison of AUC curves was calculated using Delong method. This value represents 
an estimate of the probability that a model assigns a higher risk to those who develop diabetes within an 8-year 
follow up than to those who do not. All analyses were performed using SPSS Statistics for Windows version 18.0 
(IBM, Armonk, NY). For all tests, a P value < 0.05 was considered to indicate a statistically significant difference.
Results
The anthropometric and biochemical characteristics of the subjects are summarised according to the presence 
of MAU in Table 1. MAU was observed in 365 patients (10.8%) at baseline, and the mean follow up duration 
was approximately 8 years. The development of diabetes was increased in subjects with MAU compared with 
subjects without MAU after 2 years of follow up; this gap widened over time (Fig. 1). The mean age, prevalence 
of hypertension, and level of HbA1C increased as baseline MAU category increased. Although there was no 
significant difference in the presence of metabolic syndrome, the proportions of subjects with high triglycerides 
and impaired fasting glucose were higher in the MAU group. There were no differences in activity or family his-
tory of diabetes. Of the 365 subjects with MAU, diabetes developed in 56 (15.3%) during the 10-year follow-up 
period. This proportion was statistically significantly different than that in subjects without MAU. The incidences 
of composite cardiovascular disease and each component are shown in Table 2; no significant difference was 
observed according to the presence of MAU. Using a Cox proportional hazards model, we also investigated the 
clinical impact of MAU on the development of diabetes during the follow-up period. Participants with MAU 
had a higher risk for development of diabetes (hazard ratio [HR] 1.78, 95% confidence interval [CI] 1.34–2.37, 
p value < 0.001), as shown in Table 3. Moreover, this significant association remained after adjusting for other 
risk factors for diabetes including age, prediabetes, general and abdominal obesity, and family history. We next 
performed subgroup analysis. In the non-prediabetic group, the association was even greater (HR 2.08, 95% CI 
1.07–4.03, p value 0.031), even after adjusting for confounding factors. The association between MAU and dia-
betes was more prominent in younger patients and in nonobese patients (Fig. 2). The AROC for the basic model 
and the clinical model was evaluated (Fig. 3). The AROC increased from 0.640 (95% CI, 0.609–0.671) in the basic 
model to 0.648 (95% CI, 0.617–0.678) in the clinical model. The addition of MAU to the basic model improved 
the discrimination ability; however, the AROC changed only marginally, from 0.640 to 0.648 (p value 0.099), 
when MAU was added to the clinical model.
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Discussion
In this large prospective, community-based cohort study of Korean adults, we found that MAU was associated 
with a 1.43-fold higher risk of development of diabetes after adjusting for several well-known risk factors for 
diabetes including old age, hypertension, IFG, metabolic component, and family history. The impact of MAU on 
diabetes was more prominent in subjects without prediabetes.
Several studies have investigated the association of MAU and insulin insensitivity or prediabetes6–8,11 Dutta 
et al. reported that MAU is associated with decreased reversal to normoglycemia and increased progression to 
diabetes with 147 pre-diabetic individuals with 3 months follow up12. Mykkänen et al. reported that MAU is 
Microalbuminuria (+) 
(n = 365)
Microalbuminuria (−) 
(n = 3020) P value
Age (years) 55 ± 9 52 ± 9 <0.001
Male gender 125 (34.2) 1378 (45.6) <0.001
Hypertension 72 (19.7) 351 (11.6) <0.001
Current smoking status 61 (16.7) 675 (22.4) 0.069
CAD 1 (0.3) 20 (0.7) 0.559
PAD 0 12 (0.4) 0.402
Stroke 5 (1.4) 33 (1.1) 0.746
SBP, mmHg 136 ± 23 123 ± 19 <0.001
DBP, mmHg 87 ± 13 80 ± 12 <0.001
Heart rate 66 ± 8 64 ± 8 <0.001
Metabolic syndrome 102 (27.9) 817 (27.1) 0.709
Triglyceride ≥ 150 mg/dl 186 (51.0) 1216 (40.3) <0.001
Low HDL 214 (58.6) 1696 (56.2) 0.372
Abdominal obesity 101 (27.7) 911 (30.2) 0.334
Hypertension 60 (16.4) 492 (16.3) 0.940
Impaired fasting glucose 70 (19.2) 341 (11.3) <0.001
Creatinine, mg/dl 0.8 ± 0.3 0.8 ± 0.1 0.189
HbA1C, % 5.64 ± 0.4 5.59 ± 0.3 0.007
Prediabetes 181 (49.6) 1252 (41.5) 0.004
BMI, kg/m2 24.9 ± 3.3 24.4 ± 3.1 0.003
Current alcohol 146 (40) 1345 (44.5) 0.408
Regular activity 216 (59.2) 1816 (60.1) 0.735
Family history of diabetes 37 (10.1) 294 (9.7) 0.780
Follow up duration (years) 8.3 ± 2.8 8.5 ± 2.6 0.108
Table 1. Baseline characteristics according to the presence of microalbuminuria. Values are presented as 
mean ± standard deviation or n (%). BMI, body mass index; CAD, coronary artery disease; DBP, diastolic 
blood pressure; HDL, high-density lipoprotein; HbA1c, haemoglobin A1c; PAD, peripheral artery disease; SBP, 
systolic blood pressure.
Figure 1. Diabetes free survival curve according to the incident microalbuminuria.
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Clinical event
Microalbuminuria (+) 
(n = 365)
Microalbuminuria (−) 
(n = 3020) P value
New diabetes 56 (15.3) 281 (9.3) 0.001
Composite event
 CVD 19 (5.2) 138 (4.6) 0.597
Individual events
 Stroke 7 (1.9) 55 (1.8) 0.836
 Myocardial infarction 0 24 (0.8) 0.102
 PAD 1 (0.3) 4 (0.1) 0.435
 CAD 11 (3.0) 60 (2.0) 0.242
Table 2. Incidence of diabetes and CVD (stroke, myocardial infarction, CAD, hypertension) in non-diabetic 
patients during the 10-year follow up. Values are presented as mean ± standard deviation or n (%). CAD, 
coronary artery disease; CVD, cardio-vascular disease; PAD, peripheral artery disease.
Non-adjusted †Adjusted
Hazard ratio (95% 
confidence interval) P value
Hazard ratio (95% 
confidence interval) P value
Overall population
Age ≥ 65 1.47 (1.10–2.0) 0.010 1.16 (0.86–1.55) 0.339
Hypertension 1.98 (1.59–2.47) <0.001 2.87 (0.77–10.70) 0.116
Prediabetes 8.53 (6.88–10.58) <0.001 5.98 (4.47–8.01) <0.001
Abdominal obesity 3.61 (2.91–4.48) <0.001 2.28 (1.79–2.90) <0.001
Current smoking 1.41 (1.12–1.78) 0.004 1.54 (1.21–1.95) <0.001
Family history of diabetes 1.45 (1.06–1.97) 0.020 1.58 (1.15–2.16) 0.004
BMI ≥ 25 2.07 (1.67–2.57) <0.001 1.26 (1.00–1.60) 0.049
Microalbuminuria 1.78 (1.34–2.37) <0.001 1.43 (1.07–1.91) 0.016
Regular activity 1.03 (0.83–1.29) 0.770
Non-prediabetic population Hazard ratio (95% confidence interval) P value
Hazard ratio (95% 
confidence interval) P value
Age ≥ 65 2.19 (1.10–4.34) 0.025 1.39 (0.69–2.82) 0.361
Hypertension 2.96 (1.73–5.06) <0.001 2.26 (1.28–4.00) 0.005
Abdominal obesity 2.46 (1.42–4.25) 0.001 2.26 (1.26–4.04) 0.006
Current smoking 1.68 (0.95–2.94) 0.073 2.12 (1.18–3.81) 0.012
Family history of diabetes 0.92 (0.37–2.31) 0.861
BMI ≥ 25 1.04 (0.60–1.81) 0.892
Microalbuminuria 2.78 (1.47–5.28) 0.002 2.08 (1.07–4.03) 0.031
Regular activity 0.81 (04.7–1.37) 0.425
Table 3. Multivariate analysis of the overall prevalence of diabetes and the prevalence of diabetes in non-
prediabetic subjects. BMI, body mass index.
Figure 2. Subgroup analysis for incidental development of diabetes.
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associated with insulin resistance measuring fasting insulin concentration in nondiabetic subjects13. However, 
most of these were cross-sectional studies or small population with short-term follow up data; few data are avail-
able regarding whether MAU is directly associated with overt diabetes in large nondiabetic or population-based 
cohorts.
There is a growing interest in predictors whose abnormal levels indicate an elevated risk of development of 
diabetes prior to development of clinical symptoms, since regular heath checkups are becoming increasingly 
common and often include the acquisition of data regarding left ventricular hypertrophy, MAU, high coronary 
artery calcium score, and increased carotid intima-media thickness. One previous study showed that these sub-
clinical markers are associated with an elevated risk of CVD, especially in people with metabolic syndrome and 
diabetes11. Recently, MAU was recognized as an emerging marker for cardiovascular disease in individuals with 
hypertension, obese individuals, and the general population, as well as acting as an emerging marker for diabe-
tes14–16. The relationship between MAU and insulin insensitivity is based on several pieces of epidemiological 
evidence, addressing the association of kidney dysfunction with both genetic and non-genetic markers of insulin 
resistance13,17–19. Although many reports have evaluated the relationship between MAU and prediabetes, no clear 
consensus has yet been reached. In American group, MAU did not predict incident diabetes in pre-diabetic obese 
subjects20. Recently, two cross-sectional studies were performed in Korea. Won et al.21 reported that MAU was 
associated with prediabetes, while Kim et al. concluded that the association is probably mediated by hyperten-
sion, and MAU is not independently associated with prediabetes8. However, both studies were cross-sectional in 
nature; thus, they could not show a causal relationship between MAU and prediabetes. In addition, Won et al. 
did not include HbA1c level in the definition of diabetes, which might have led to an underestimation of the real 
prevalence of diabetes.
A unique aspect of our study is that we showed a direct association between MAU and incidence of diabetes 
using a large, nationwide cohort with a mean follow up duration of 8 years. After adjusting for traditional risk fac-
tors for diabetes including pre-diabetes and components of metabolic syndrome, the association was still signifi-
cant. Since the impact of MAU was also statistically significant in subjects without prediabetes, we conclude that 
MAU is potentially an early marker for diabetes, similar to pre-diabetes. Although the precise mechanism of pro-
gression to the diabetes in subjects with MAU is not understood, several epidemiologic and experimental studies 
have reported potential mechanisms by which insulin resistance is linked to kidney dysfunction in both diabetic 
and non-diabetic subjects. For instance, there were epidemiologic studies showed that MAU may precede the 
onset of diabetes12,22 in non-diabetic patients. In addition, insulin insensitivity observed in non-diabetic subjects 
with MAU13 causes podocyte apoptosis and detachment from the glomerular basement membrane23 and insulin 
insensitivity also plays an important role in the development of albuminuria due to endothelial dysfunction and 
increased vascular permeability, even in non-diabetic patients24.
Although we included a large number of participants extracted by stratified random sampling with propor-
tional allocation among the 1476 categories and tried to adjust for confounding factors, this study had some 
limitations. First, it was difficult to replicate our findings due to lack of availability of another cohort. Thus, lack 
of replication of our result is one of the major limitations. Second, urinary albumin was assessed in only a single 
urine specimen per participant. Since urinary albumin level can exhibit considerable intra-individual variabil-
ity, the lack of repeated sampling could have missed this variation and is thus a limitation. However, there were 
several studies to evaluate the diagnostic performance of spot urine for the detection of MAU, since 24-hour 
urine collection is time and cost consuming. They showed that spot urine was a reliable measure of proteinuria 
in various subjects with diabetes, prediabetes, chronic kidney disease and rheumatic disease as well as in general 
population25–31. Third, MAU could transiently develop in the presence of inflammation or stress. However, we 
could not fully exclude such conditions, since these data were derived from a nationwide heath cohort. Therefore, 
another limitation is that we might have overestimated the prevalence of MAU. Fourth, this study was restricted 
to only Koreans. Therefore, these results might not be applicable to other ethnic groups.
In conclusion, incident MAU could be an early marker for diabetes, even in the non-prediabetic population. 
Thus, physicians should closely monitor all subjects and regularly measure HbA1C level. Patients should also be 
educated about lifestyle modifications including weight control, alcohol cessation, and regular activity.
Figure 3. ROC curve for the prediction of diabetes in the basic and the clinical model.
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